Humaid Al-Shamsi, CEO of Burjeel Cancer Institute (BCI) Comprehensive Cancer Center, shared a post on LinkedIn:
“Excited to share that our abstract ‘Beyond ESR1: multi-pathway genomic drivers of endocrine resistance in HR+/HER2- breast cancer’ was presented at ASCO2026!
This work highlights the importance of looking beyond ESR1 mutations to understand the complex, multi-pathway genomic mechanisms driving endocrine resistance in HR+/HER2- breast cancer. Through comprehensive genomic analysis of 1,429 samples, we identified frequent alterations in PI3K/AKT, FGFR, ERBB2, MAPK, and cell-cycle pathways – offering new insights for more effective treatment strategies.
A big thank you to all my esteemed collaborators and co-authors for their outstanding contributions and dedication to advancing precision oncology: Datar Cancer Genetics Europe GmbH, Rajan Datar, Vineet Datta, Darshana Patil, Massimo Cristofanilli, Stefan Schuster, Sewanti Limaye and Ashok K Vaid.
Special gratitude to the leadership and research teams at Datar Cancer Genetics Europe GmbH , Dana-Farber Cancer Institute , Cromwell Hospital and Burjeel Cancer Institute (BCI) For their continued support and vision in strengthening cancer care globally.
Proud to contribute to this important work that moves us closer to personalized therapies for our patients.
Looking forward to publish this work together.”
Other articles featuring Humaid Al-Shamsi on OncoDaily.
